Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy (vol 31, S472, 2020)

被引：0
|
作者：
Liu, S. V. [1 ]
De Braud, F. [2 ]
Drilon, A. [3 ]
Doebele, R. C. [4 ]
Patel, M. R. [5 ]
Cho, B. C. [6 ]
Ahn, M. J. [7 ]
Chiu, C. H. [8 ]
Farago, A. F. [9 ]
Goto, K. [10 ]
Lee, J. [7 ]
Ohe, Y. [11 ]
Ou, S. H. I. [12 ]
Cassier, P. [13 ]
Tan, D. S. W. [14 ]
Otterson, G. A. [15 ,16 ]
Veronese, L. [17 ]
Osborne, S. [17 ]
Simmons, B. [18 ]
Siena, S. [19 ,20 ]
机构：
[1] Georgetown Univ, Washington, DC 20057 USA
[2] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol & Hematol, Milan, Italy
[3] Mem Sloan Kettering Canc Ctr, Dept Med, Div Solid Tumor Oncol, Thorac Oncol Serv, 1275 York Ave, New York, NY 10021 USA
[4] Univ Colorado, Aurora, CO USA
[5] Univ Minnesota, Dept Med, Box 736 UMHC, Minneapolis, MN 55455 USA
[6] Yonsei Canc Ctr, Seoul, South Korea
[7] Sungkyunkwan Univ, Div Hematol Oncol, Samsung Med Ctr, Dept Med,Sch Med, Seoul, South Korea
[8] Taipei Vet Gen Hosp, Dept Chest Med, Taipei, Taiwan
[9] Massachusetts Gen Hosp, Boston, MA 02114 USA
[10] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[11] Natl Canc Ctr, Tokyo, Japan
[12] Univ Calif Irvine, Sch Med, Irvine, CA 92717 USA
[13] Ctr Leon Berard, Dept Med Oncol, Lyon, France
[14] Natl Canc Ctr, Div Med Oncol, Singapore, Singapore
[15] Ohio State Univ, Ctr Comprehens Canc, Arthur G James Canc Hosp, Columbus, OH 43210 USA
[16] Ohio State Univ, Ctr Comprehens Canc, Richard J Solove Res Inst, Columbus, OH 43210 USA
[17] F Hoffmann La Roche Ltd, Basel, Switzerland
[18] Genentech Inc, San Francisco, CA 94080 USA
[19] Univ Milan, Dept Oncol & Hematooncol, Milan, Italy
[20] Metropolitano Niguarda, Niguarda Canc Ctr, Grande Osped, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷 / 04期
关键词：
D O I：
10.1016/j.annonc.2021.01.008
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：577 / 577
页数：1
相关论文
共 50 条
  • [31] Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
    De Braud, F. G. M.
    Siena, S.
    Barlesi, F.
    Drilon, A.
    Simmons, B. P.
    Huang, X.
    Ye, C.
    Doebele, R. C.
    ANNALS OF ONCOLOGY, 2019, 30 : 609 - 609
  • [32] Entrectinib in Locally Advanced / Metastatic ROS1 and NTRK Fusion-Positive (NTRK plus ) Non-Small Cell Lung Cancer (NSCLC): Updated Integrated Analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
    Springfeld, Christoph
    de Braude, Filippo
    Siena, Salvatore
    Barlesi, Fabrice
    Drilon, Alexander
    Simmons, Brian
    Huang, Xinhui
    Pitcher, Bethany
    Doebele, Robert C.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 235 - 235
  • [33] Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials (vol 21, pg 261, 2020)
    Drilon, A.
    Siena, S.
    Dziadziuszko, R.
    LANCET ONCOLOGY, 2020, 21 (02): : E70 - E70
  • [34] Efficacy and safety of entrectinib in locally advanced/metastatic ROS1 fusion-positive NSCLC: An updated integrated analysis
    Krebs, M. G.
    De Braud, F.
    Siena, S.
    Drilon, A.
    Doebele, R. C.
    Patel, M. R.
    Cho, B. C.
    Liu, S. V.
    Ahn, M-J.
    Chiu, C-H.
    Farago, A. F.
    Lin, C-C.
    Karapetis, C. S.
    Li, Y-C.
    Barlesi, F.
    Simmons, B.
    Pitcher, B.
    Dziadziuszko, R.
    ANNALS OF ONCOLOGY, 2020, 31 : S831 - S833
  • [35] Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
    de Braud, F.
    Siena, S.
    Barlesi, F.
    Drilon, A.
    Simmons, B.
    Huang, X.
    Osborne, S.
    Doebele, R. C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [36] Pre- and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumours treated with entrectinib
    Dziadziuszko, Rafal
    Hung, Tiffany
    Wang, Kun
    Choeurng, Voleak
    Drilon, Alexander
    Doebele, Robert C.
    Barlesi, Fabrice
    Wu, Charlie
    Dennis, Lucas
    Skoletsky, Joel
    Woodhouse, Ryan
    Li, Meijuan
    Chang, Ching-Wei
    Simmons, Brian
    Riehl, Todd
    Wilson, Timothy R.
    MOLECULAR ONCOLOGY, 2022, 16 (10) : 2000 - 2014
  • [37] Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
    Liu, Dazhi
    Offin, Michael
    Harnicar, Stephen
    Li, Bob T.
    Drilon, Alexander
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2018, 14 : 1247 - 1252
  • [38] Entrectinib in Chinese (mainland China, Hong Kong, Taiwan) patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC and NTRK-fp solid tumours
    Lu, S.
    Chiu, C-H.
    Yu, Y.
    Loong, H. H. F.
    Lin, C. C.
    Hu, X.
    Dong, X.
    Li, J.
    Zhao, J.
    Ye-Hui, S.
    Zhang, Z.
    Zhao, N.
    Xia, J.
    Wang, D.
    Fan, Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S83 - S84
  • [39] Patient reported outcomes (PROs) analysis for patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) receiving entrectinib in the global phase II STARTRK-2 study
    Barlesi, F.
    Wolf, J.
    Ahn, M-J.
    Doebele, R. C.
    Paz-Ares, L.
    Rolfo, C.
    Siena, S.
    Seto, T.
    Ohe, Y.
    Ou, S. H. I.
    Krebs, M. G.
    Kapre, A.
    Piault-Louis, E.
    McCallum, S.
    Osborne, S.
    Aziez, A.
    Drilon, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S1391 - S1392
  • [40] Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer
    Horiike, Atsushi
    Takeuchi, Kengo
    Uenami, Takeshi
    Kawano, Yuko
    Tanimoto, Azusa
    Kaburaki, Kyohei
    Tambo, Yuichi
    Kudo, Keita
    Yanagitani, Noriko
    Ohyanagi, Fumiyoshi
    Motoi, Noriko
    Ishikawa, Yuichi
    Horai, Takeshi
    Nishio, Makoto
    LUNG CANCER, 2016, 93 : 43 - 46
12345